Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence

American Journal on Addictions

Volumn 18, Issue 4, 2009, Pages 301-308

  Raby, Wilfrid Noel ^a   Carpenter, Kenneth M ^a   Rothenberg, Jami ^a   Brooks, Adam C ^a,b   Jiang, Huiping ^a   Sullivan, Maria ^a   Bisaga, Adam ^a   Comer, Sandra ^a   Nunes, Edward V ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DIAMORPHINE; NALTREXONAZINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG DOSE TITRATION; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; PROGNOSIS; THERAPY EFFECT; URINALYSIS;

ADULT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; NALTREXONE; NARCOTICS; OPIOID-RELATED DISORDERS; RETENTION (PSYCHOLOGY); TIME FACTORS;

EID: 67651252070     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490902927785     Document Type: Article

References (74)

1. Blanco C, Alderson D, Ogburn E, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend. 2007;90:252-260.
2. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid maintenance. Cochrane Database Syst Rev. 2008;16:CD002207.
3. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101:491-503.
4. Davoli M, Perucci CA, Forastiere F, Doyle P, Rapiti E, Zaccarelli M. Risk factors for overdose mortality: a case-controlled study within a cohort of intravenous drug users. Int. J Epidemiol. 1993;22:273-277.
5. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90:1100-1111.
6. Mertens JR, Weisner CM. Predictors of substance abuse treatment retention among women and men in an HMO. Alcohol Clin Exp Res. 2000;24:1525-1533.
7. Saxon AJ, Wells EA, Fleming C, Jackson TR, Calsyn DA. Pre-treatment characteristics, program philosophy, and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction. 1996;91:1197-1209.
8. Stark MJ. Dropping out of substance abuse treatment: a clinically oriented review. Clin Psychol Rev. 1992;12:93-116.
9. Caplehorn JRM, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust. 1991;154:195-199.
10. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.
11. Torrens M, Castillo C, Perez-Sola V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 1996;41:55-59.
12. Del Rio M, Mino A, Perneger TV. Predictors of patient retention in a newly established methadone maintenance treatment program. Addiction. 1997;92:1353-1360.
13. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health. 1998;88:34-39.
14. Caplehorn JRM, Lumley TS, Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug Alcohol Depend. 1998;52:57-61.
15. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000;57:395-404.
16. Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage 1 trial. Am J Addict. 2006;15:150-159.
17. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatment alone for treatment of opioid dependence (review). The Cochrane Library. 2006;3:1-30.
18. Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend. 2006;83:218-224.
19. Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54:127-135.
20. Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58:755-761.
21. Carroll KM, Sinha R, Nich C, Babuscio T, Rounsaville BJ. Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Exp Clin Psychopharmacol. 2002;10:54-63.
22. Fals-Steward W, O'Farrell TJ. Behavioral family counseling and nal-trexone for male opioid dependent patients. J Consult Clin Psychol. 2003;71:432-442.
23. Church SH, Rothenberg JL, Sullivan MA, Bornstein G, Nunes EV. Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence. Am J Drug Alcohol Abuse. 2001;27:441-452.
24. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral Therapy to Augment Oral Naltrexone for Opioid Dependence: A Ceiling on Effectiveness? Am J Drug Alcohol Depend. 2006;32:503-517.
25. Nirenberg TD, Celluci T, Liepman MR, Swift R, Sirota D. Cannabis versus other illicit drug use among methadone maintenance patients. Psychol Addict Behav. 1996;10:222-227.
26. DeMaria PA, Sterling R,Weinstein SP. The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment. Am J Addict. 2000;9:145-153.
27. Ellner M. Marijuana use by heroin abusers as a factor in program retention. J Consult Clin Psychol. 1977;45:709-710.
28. Budney AJ, Bickel WK, Amass L. Marijuana Use and treatment outcome among opioid-dependent patients. Addiction. 1998;93:493-503.
29. Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Cannabis abuse is not a risk factor for treatment outcomein methadone maintenance treatment: a 1-year prospective study in an Israeli clinic. Aust NZ J Psychiatry. 2004;38:42-46.
30. Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98:269-279.
31. Rothenberg J, Sullivan MA, Church SH, et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Ab Res. 2002;23:351-360.
32. Carroll KM, Nuro KR, O'Malley SS. Compliance enhancement: a manual for the clinical management of drug-dependent patients. Yale University School of Medicine, New Haven, CT, Psychotherapy Development Center, Department of Psychiatry; 1999.
33. Nunes EV, Goehl L, Seracini A, et al. Evaluation of depression and panic disorder in methadone patients using a modification of the structured clinical interview for DSM-III-R: test-retest reliability. Am J Addict. 1996;5:241-248.
34. Miller WR, Rollnick S. Motivational Interviewing. London, England: Guilford Press; 2002.
35. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry. 1994;51:989-997.
36. Marlot GA, Gordon JR. Relapse prevention and maintenance strategies in the treatment of addictive behaviors. New York, NY: Guilford Press; 1985.
37. Silverman K, Wong CJ, Umbricht-Schneider A, Montoya ID, Schuster CR, Preston KL. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol. 1998;66:811-824.
38. Silverman K, Chutuape MA, Bigelow GE, Stitzer ML. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharm. (Berlin). 1999;146:128-138.
39. Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effect on drug use of methadone maintenance patients. J Consult Clin Psychol. 1992;60:927-934.
40. Higgins ST, Delaney DD, Budney AJ, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991;148:1218-1224.
41. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-769.
42. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994;51:568-576.
43. Galanter M. Network therapy for addiction: a model for office practice. Am J Psychiatry. 1993;150:28-36.
44. Wang D, Raehal KM, Bilsky EJ, Sadee W. Inverse agonists and neutral antagonists at mu opioid receptors (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem. 2001;77:1590-1600.
45. Raehal KM, Lowery JJ, Bhamidipati CM, et al. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther. 2005;313:1150-1162.
46. Divin MF, Holden Ko MC, Traynor JR. Comparison of opioid receptor antagonist properties of naltrexone and 6beta-naltrexol in morphine-näive and morphine-dependent mice. Eur J Pharmacol. 2008;583:48-55.
47. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and Naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse. 1987;13:1-17.
48. Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2004;Oct 18;(4):CD002024.
49. Muntoni AL, Pillolla G, Melis M, Perra S, Gessa GL, Pistis M. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neuroscience. 2006;23:2385-2394.
50. Poddar MK, Dewey WL. Effects of cannabinoids on catcholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther. 1980;214:63-67.
51. Jentsch DJ, Andrusiak BS, Tran A, Bowers MB, Roth RH. Delta-9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopahrmacology. 1997;16:426-432.
52. Schlicker E, Timm J, Zentner J, Gothert M. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiederbergs Arch. Pharmacol. 1997;356:583-589.
53. Kathmann M, Bauer U, Schlicker E, Golthert M. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainite stimulated nora-drenaline and dopamine release in the brain. Naunyn Schmiederbergs Arch. Pharmacol. 1999;359:466-470.
54. Trendelenburg AU, Cox SL, Schelb V, Klebroff W, Khairallah L, Starke K. Modulation of (3)H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and beta-adrenoreceptors in mouse tissues. Br J Pharmacol. 2000;130:321-330.
55. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001;22:565-572.
56. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG. The cannabinoid CB(1) receptor antagonist SR141716A increases nore-pinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol. 2001;426:R3-R4.
57. Tzavara ET, Davis RJ, Perry KW, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol. 2003;138:544-553.
58. Moranta D, Esteban S, Garcia-Sevilla JA. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiederbergs Arch Pharmacol. 2004;369:516-524.
59. Oropeza VC, Page ME, Van Bockstaele EJ. Systemic administration of WIN55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res. 2005;1046:45-54.
60. Niederhoffer N, Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol. 1999;126:457-466.
61. Vizi ES, Katona I, Freund TF. Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung. Eur J Pharmacol. 2001;431:237-244.
62. Pfizer T,NiederhofferN,Szabo B.Search foran endogenous cannabinoid-mediated effect in the sympathetic nervous system. Naunyn Schmiedeberg Arch Pharmacol. 2005;371:9-17.
63. Ponto LL, O'Leary DS, Koeppel J, et al. Effects of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O]water: effects in occasional and chronic users. J Clin Pharmacol. 2004;44:751-766.
64. Aviello G, Romano B, Izzo AA. Cannabinoid and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci. 2008;Suppl. 1:81-93.
65. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliviera LM, Da Silviera DX. Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care. (Engl) 2008;17:431-443.
66. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharma-cotherapy and behavioral interventions for alcohol dependence. JAMA. 2006;295:2003-2017.
67. Kranzler HR, Wesson DR, Billot L, Drug Abuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051-1059.
68. Vasquez C, Lewis DK. The CB1 cannabinoid receptor can sequester G-proteins making them unavailable to couple to other receptors. J Neurosci. 1999;19:9271-9280.
69. Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage 1 trial. Am J Addict. 2006;15:150-159.
70. Carpenter KM, Jiang H, Sullivan MA, et al. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav. 2009;23:47-55.
71. Mason DJ, Lowe J, Welch SP. A diminution of delta-9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development. Eur J Pharmacology. 1999;381:105-111.
72. Shedler J, Block J. Adolescent drug use and psychological health. Am Psychol. 1990;45:612-630.
73. Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berlin). 2003;166:77-85.
74. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology. 2007;32:1391-1403.